{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:49:23Z","timestamp":1794019763307,"version":"4.8.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["9039\u201300015B"],"award-info":[{"award-number":["9039\u201300015B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["00015B"],"award-info":[{"award-number":["00015B"]}],"id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.biopha.2022.112687","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T07:35:20Z","timestamp":1645774520000},"page":"112687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy"],"prefix":"10.1016","volume":"148","author":[{"given":"Anders Kirkegaard","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Chatzidionysiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Kirkegaard","family":"Torp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sofie","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene Broch","family":"Tenstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin S.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kostine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Leipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tue Wenzel","family":"Kragstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112687_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12832","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis","volume":"294","author":"Cappelli","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biopha.2022.112687_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.112687_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 blockade expands intratumoral memory T cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2022.112687_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.biopha.2022.112687_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2022.112687_bib6","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2022.112687_bib7","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.112687_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/1744666X.2017.1233816","article-title":"Recent advances and future directions in understanding and treating Chlamydia-induced reactive arthritis","volume":"13","author":"Carter","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.biopha.2022.112687_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11926-020-00904-9","article-title":"Reactive arthritis: treatment challenges and future perspectives","volume":"22","author":"Wendling","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.biopha.2022.112687_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.idc.2017.01.002","article-title":"Reactive arthritis","volume":"31","author":"Schmitt","year":"2017","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.biopha.2022.112687_bib11","doi-asserted-by":"crossref","first-page":"15131","DOI":"10.1038\/s41598-020-71674-8","article-title":"Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach","volume":"10","author":"Verma","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.112687_bib12","unstructured":"Elicabe, R.J. & Genaro, M.S. D."},{"key":"10.1016\/j.biopha.2022.112687_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol., Immunother.: CII"},{"key":"10.1016\/j.biopha.2022.112687_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2022.112687_bib15","article-title":"Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer","author":"Cunningham-Bussel","year":"2021","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biopha.2022.112687_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/BOR.0000000000000701","article-title":"Treatment of immune checkpoint inhibitor-induced inflammatory arthritis","volume":"32","author":"Jeurling","year":"2020","journal-title":"Curr. Opin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.biopha.2022.112687_bib19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/BOR.0000000000000601","article-title":"Arthritis risk with immune checkpoint inhibitor therapy for cancer","volume":"31","author":"Pundole","year":"2019","journal-title":"Curr. Opin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib21","doi-asserted-by":"crossref","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58","author":"Kostine","year":"2019","journal-title":"Rheumatol. (Oxf.)"},{"key":"10.1016\/j.biopha.2022.112687_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s41927-020-00133-8","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps","volume":"4","author":"Cappelli","year":"2020","journal-title":"BMC Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.112687_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","article-title":"Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma","volume":"38","author":"Chan","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/j.biopha.2022.112687_bib25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10067-018-4035-0","article-title":"Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment","volume":"37","author":"Inamo","year":"2018","journal-title":"Clin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib26","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2169\/internalmedicine.2556-19","article-title":"Tenosynovitis induced by an immune checkpoint inhibitor: a case report and literature review","volume":"58","author":"Murakami","year":"2019","journal-title":"Intern Med."},{"key":"10.1016\/j.biopha.2022.112687_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.112687_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.biopha.2022.112687_bib29","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatol. (Oxf.)"},{"key":"10.1016\/j.biopha.2022.112687_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2022.112687_bib31","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1007\/s10067-020-05162-9","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis","volume":"39","author":"Liu","year":"2020","journal-title":"Clin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2022.112687_bib33","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3899\/jrheum.130136","article-title":"Attack rate of Chlamydia-induced reactive arthritis and effect of the CCR5-Delta-32 mutation: a prospective analysis","volume":"40","author":"Carter","year":"2013","journal-title":"J. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib34","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s10067-016-3364-0","article-title":"The incidence of sexually acquired reactive arthritis: a systematic literature review","volume":"35","author":"Denison","year":"2016","journal-title":"Clin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib35","first-page":"2185","article-title":"On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany","volume":"27","author":"Braun","year":"2000","journal-title":"J. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.berh.2011.01.018","article-title":"Reactive arthritis","volume":"25","author":"Hannu","year":"2011","journal-title":"Best. Pr. Res Clin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rdc.2009.03.010","article-title":"Reactive arthritis: clinical aspects and medical management","volume":"35","author":"Carter","year":"2009","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.biopha.2022.112687_bib38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5455\/medarh.2015.69.42-45","article-title":"Modes of presentation of reactive arthritis based on the affected joints","volume":"69","author":"Lahu","year":"2015","journal-title":"Med Arch."},{"key":"10.1016\/j.biopha.2022.112687_bib39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jbspin.2017.01.013","article-title":"A bicentre retrospective study of features and outcomes of patients with reactive arthritis","volume":"85","author":"Courcoul","year":"2018","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.biopha.2022.112687_bib40","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10067-018-4022-5","article-title":"Reactive arthritis: update 2018","volume":"37","author":"Garc\u00eda-Kutzbach","year":"2018","journal-title":"Clin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib41","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s11926-996-0012-8","article-title":"Pathogenesis of reactive arthritis","volume":"3","author":"Sieper","year":"2001","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.biopha.2022.112687_bib42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/jdv.12741","article-title":"Reactive arthritis","volume":"29","author":"Stavropoulos","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.biopha.2022.112687_bib43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int J. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.112687_bib44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr.23467","article-title":"Arthritis after cancer immunotherapy: symptom duration and treatment response","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis care Res."},{"key":"10.1016\/j.biopha.2022.112687_bib45","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding","volume":"59","author":"Daoussis","year":"2020","journal-title":"Rheumatol. (Oxf.)"},{"key":"10.1016\/j.biopha.2022.112687_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.biopha.2022.112687_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211006963","article-title":"Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis","volume":"13","author":"Verspohl","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.biopha.2022.112687_bib48","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.112687_bib49","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/rheumatology\/key234","article-title":"High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis","volume":"57","author":"Ford","year":"2018","journal-title":"Rheumatol. (Oxf.)"},{"key":"10.1016\/j.biopha.2022.112687_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-238851","article-title":"First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis","volume":"14","author":"Murray","year":"2021","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.biopha.2022.112687_bib51","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/art.1780391211","article-title":"Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter\u2019s syndrome). A department of veterans affairs cooperative study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2022.112687_bib52","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3899\/jrheum.191307","article-title":"Outcomes and safety of tumor necrosis factor inhibitors in reactive arthritis: a nationwide experience from Iceland","volume":"47","author":"Thorsteinsson","year":"2020","journal-title":"J. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib53","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/art.30272","article-title":"Safety and efficacy of anti-tumor necrosis factor \u03b1 therapy in ten patients with recent-onset refractory reactive arthritis","volume":"63","author":"Meyer","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2022.112687_bib54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jbspin.2016.02.022","article-title":"Anti-TNF treatment of reactive arthritis. A monocentric experience","volume":"84","author":"Brinster","year":"2017","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.biopha.2022.112687_bib55","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21323","article-title":"Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial","volume":"53","author":"Flagg","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2022.112687_bib56","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/art.24899","article-title":"Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"61","author":"Tanaka","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2022.112687_bib57","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib58","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.biopha.2022.112687_bib59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune checkpoint inhibitor-induced musculoskeletal manifestations","volume":"41","author":"Angelopoulou","year":"2020","journal-title":"Rheuma Int."},{"key":"10.1016\/j.biopha.2022.112687_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-020-00167-1","article-title":"The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition","volume":"9","author":"Risbjerg","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2022.112687_bib61","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2022.112687_bib62","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2022.112687_bib63","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.112687_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/acr.23865","article-title":"Systematic review of recommendations on the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer","volume":"72","author":"Lopez-Olivo","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.biopha.2022.112687_bib65","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.13102","article-title":"Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: a systematic review and meta-analysis","volume":"2","author":"Bilal","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.biopha.2022.112687_bib66","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/0956462414540617","article-title":"European Guideline on the management of sexually acquired reactive arthritis","volume":"25","author":"Carlin","year":"2014","journal-title":"Int J. STD AIDS"},{"key":"10.1016\/j.biopha.2022.112687_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2022.112687_bib68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.112687_bib69","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.112687_bib70","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2022.112687_bib71","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/03009740310000157","article-title":"Treatment of reactive arthritis with infliximab","volume":"32","author":"Oili","year":"2003","journal-title":"Scand. J. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib72","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jbspin.2016.05.002","article-title":"Early treatment of reactive arthritis with etanercept and 2 years follow-up","volume":"84","author":"Courcoul","year":"2017","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.biopha.2022.112687_bib73","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/RHU.0b013e3180690c1f","article-title":"Use of adalimumab in poststreptococcal reactive arthritis","volume":"13","author":"S\u00e1nchez-Cano","year":"2007","journal-title":"J. Clin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10067-007-0692-0","article-title":"Successful use of infliximab in the treatment of Reiter\u2019s syndrome: a case report and discussion","volume":"27","author":"Gill","year":"2008","journal-title":"Clin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/RHU.0b013e3181d06f70","article-title":"Prolonged remission of chronic reactive arthritis treated with three infusions of infliximab","volume":"16","author":"Wechalekar","year":"2010","journal-title":"J. Clin. Rheuma"},{"key":"10.1016\/j.biopha.2022.112687_bib76","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00296-009-0965-9","article-title":"Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection","volume":"30","author":"Schafranski","year":"2010","journal-title":"Rheuma Int"},{"key":"10.1016\/j.biopha.2022.112687_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00296-011-2000-1","article-title":"Successful use of etanercept for the treatment of Reiter\u2019s syndrome: a case report and review of the literature","volume":"32","author":"Edrees","year":"2012","journal-title":"Rheuma Int"},{"key":"10.1016\/j.biopha.2022.112687_bib78","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jbspin.2012.03.001","article-title":"Spectacular evolution of reactive arthritis after early treatment with infliximab","volume":"79","author":"Thomas-Pohl","year":"2012","journal-title":"Jt. Bone Spine"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:33:45Z","timestamp":1781764425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":78,"alternative-id":["S0753332222000750"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112687","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112687"}}